Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort studyCraig Haifer, Lena Thin, Daniel R. van Langenberg et al.|The Medical Journal of Australia|2020Cited by 22
Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for ConcernPaulina Suo, Craig Haifer, Ashish Srinivasan et al.|Journal of Gastroenterology and Hepatology|2025Cited by 0